OncoMatch/Clinical Trials/NCT05887609
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
Is NCT05887609 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Mirvetuximab Soravtansine-gynx and Olaparib for ovary cancer.
Treatment: Mirvetuximab Soravtansine-gynx · Olaparib — The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Biomarker criteria
Required: FOLR1 high or medium expression (high or medium)
Allowed: BRCA1 any mutation
Allowed: BRCA2 any mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — recurrent disease
Patients must have received at least one prior platinum-based chemotherapy regimen for platinum sensitive recurrent disease
Must have received: PARP inhibitor — treatment or maintenance
if BRCA mutation positive, must have received a prior PARP inhibitor as either treatment or maintenance therapy
Cannot have received: FRα-targeting agent (mirvetuximab soravtansine)
Patients who received prior treatment with MIRV or other FRα- targeting agents
Cannot have received: allogenic bone marrow transplant or double umbilical cord blood transplantation
Previous allogenic bone marrow transplant or double umbilical cord blood transplantation (dUCBT)
Lab requirements
Blood counts
ANC ≥ 1.5 x 10^9/L (1500/µL); platelets ≥ 100 x 10^9/L (100,000/µL); hemoglobin ≥ 10.0 g/dL with no blood transfusion in past 28 days
Kidney function
serum creatinine ≤ 1.5 x ULN; creatinine clearance ≥51 mL/min (Cockcroft-Gault or 24h urine)
Liver function
AST/ALT ≤ 2.5 x ULN unless liver metastases are present in which case ≤ 5x ULN; serum bilirubin ≤ 1.5 x ULN (Gilbert syndrome eligible if total bilirubin < 3.0 x ULN); serum albumin ≥ 2 g/dL
Patients must have adequate hematologic, liver, and kidney function as defined as: ANC ≥ 1.5 x 10^9/L (1500/µL); Platelet count ≥ 100 x 10^9/L (100,000 µL); Hemoglobin ≥ 10.0 g/dL with no blood transfusion in the past 28 days; Serum creatinine ≤ 1.5 x ULN; creatinine clearance ≥51 mL/min; AST/ALT ≤ 2.5 x ULN unless liver metastases are present in which case ≤ 5x ULN; serum bilirubin ≤ 1.5 x ULN (Gilbert syndrome eligible if total bilirubin < 3.0 x ULN); serum albumin ≥ 2 g/dL
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Colorado Hospital · Aurora, Colorado
- Northwestern Memorial Hospital · Chicago, Illinois
- University of Pennsylvania Health System, Perelman Center for Advanced Medicine · Philadelphia, Pennsylvania
- UPMC Magee-Women's Hospital · Pittsburgh, Pennsylvania
- University of Wisconsin - Carbone Cancer Center - University Hospital · Madison, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify